135 related articles for article (PubMed ID: 1455396)
1. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
McLaughlin LF; Drummond O; MacGregor IR
Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
[TBL] [Abstract][Full Text] [Related]
2. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
[TBL] [Abstract][Full Text] [Related]
3. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
4. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
Prowse CV; Williams AE
Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
7. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo.
Hedner U; Nilsson IM; Bergentz SE
Thromb Haemost; 1976 Apr; 35(2):386-95. PubMed ID: 989639
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and in vivo properties of high purity factor IX concentrates.
Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
[TBL] [Abstract][Full Text] [Related]
10. Increased fibrinopeptide A after prothrombin complex concentrates.
Viganó S; Cattaneo M; Gervasoni W; Mannucci PM
Thromb Haemost; 1980 Oct; 44(2):72-5. PubMed ID: 6779400
[TBL] [Abstract][Full Text] [Related]
11. Thrombogenicity of a factor IX concentrate quantitated in a canine model.
MacGregor IR; Ferguson JF; Dawes J; McLaughlin L; Prowse CV
Blood Coagul Fibrinolysis; 1990; 1(1):23-30. PubMed ID: 2102787
[TBL] [Abstract][Full Text] [Related]
12. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
[TBL] [Abstract][Full Text] [Related]
13. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
[TBL] [Abstract][Full Text] [Related]
14. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
Small M; Lowe GD; Douglas JT; Forbes CD; Prentice CR
Thromb Haemost; 1982 Aug; 48(1):76-7. PubMed ID: 7135346
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates.
Köhler M; Hellstern P; Lechler E; Uberfuhr P; Müller-Berghaus G
Thromb Haemost; 1998 Sep; 80(3):399-402. PubMed ID: 9759617
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
Herzog E; Kaspereit FJ; Krege W; Doerr B; van Ryn J; Dickneite G; Pragst I
Thromb Res; 2014 Sep; 134(3):729-36. PubMed ID: 25084749
[TBL] [Abstract][Full Text] [Related]
17. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal.
Pabinger I; Tiede A; Kalina U; Knaub S; Germann R; Ostermann H;
Ann Hematol; 2010 Mar; 89(3):309-16. PubMed ID: 19787352
[TBL] [Abstract][Full Text] [Related]
18. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
[TBL] [Abstract][Full Text] [Related]
19. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors--benefits and limitations.
Lusher JM
Semin Hematol; 1994 Apr; 31(2 Suppl 4):49-52. PubMed ID: 7939776
[TBL] [Abstract][Full Text] [Related]
20. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
